Log in

Relevant bibliographies by topics / Bare Metal Stent (BMS) / Journal articles

To see the other types of publications on this topic, follow the link: Bare Metal Stent (BMS).

Journal articles on the topic 'Bare Metal Stent (BMS)'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Bare Metal Stent (BMS).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mowakeaa, Samer, Aline Iskandar, and Nikolaos Kakouros. "Neoatherosclerosis in Very Late Stenosis of Bare Metal Stent by Optical Coherence Tomography." Case Reports in Cardiology 2016 (2016): 1–3. http://dx.doi.org/10.1155/2016/1652065.

Full text

Abstract:

Bare metal stents (BMS) continue to be widely used in patients with coronary artery disease undergoing percutaneous revascularization. Progressive luminal renarrowing has been reported late after BMS implantation resulting in a significant rate of stent failure events. We present a case of very late BMS failure due to in-stent restenosis where optical coherence tomography (OCT) was used to demonstrate neoatherosclerosis as the underlying mechanism. We provide a brief review of neoatherosclerosis and showcase salient features on OCT evaluation.

APA, Harvard, Vancouver, ISO, and other styles

2

Zhao, Yaping, Zhong Chen, Wayne W. Zhang, Sheng Wang, Yaoguo Yang, and Liao Yang. "Bioabsorbable Drug-Eluting Stent Versus Bare Metal Stent in Iliac Artery Evaluated by Optical Coherence Tomography: An In Vivo Study in Porcine." Vascular and Endovascular Surgery 52, no. 7 (2018): 512–19. http://dx.doi.org/10.1177/1538574418783528.

Full text

Abstract:

Objective: This study aimed to compare, using optical coherence tomography (OCT), the outcomes of bioabsorbable drug-eluting stent with those of bare metal stent (BMS) following implantation in porcine iliac artery. Methods: After the placement of BMS and bioabsorbable drug-eluting stents, we used OCT and digital subtraction angiography to investigate stent appositions, arterial neointima, evagination, and restenosis at 1 and 3 months. Results: At 1 and 3 months after stent implantation, OCT study was performed to investigate 32 stents and 21 788 struts. Thirty-three malapposed struts were fou

APA, Harvard, Vancouver, ISO, and other styles

3

Rao K, Raghavendra, S. Reddy, J. R. Kashyap, K. Vikas, Hithesh Reddy, and Vadivelu Ramalingam. "Acute Coronary Syndrome after 17 Years of Bare Metal Stent Implantation: “Very” Very Late Stent Thrombosis." Case Reports in Cardiology 2020 (February 6, 2020): 1–5. http://dx.doi.org/10.1155/2020/9628719.

Full text

Abstract:

Very late stent thrombosis (VLST) is a catastrophic and life-threatening complication after percutaneous coronary intervention which presents as an acute coronary syndrome with significantly high mortality and morbidity. VLST is a rare entity with drug-eluting stents and even rarer with bare metal stents. The exact pathophysiologic mechanism of VLST after BMS implantation is not known although various mechanisms have been proposed. Recently, in-stent neoatherosclerosis with intimal plaque rupture has been proposed as a potential mechanism of VLST after BMS. We report a rare case of VLST occurr

APA, Harvard, Vancouver, ISO, and other styles

4

Cornelissen, Anne, Liang Guo, Raquel Fernandez, et al. "Endothelial Recovery in Bare Metal Stents and Drug-Eluting Stents on a Single-Cell Level." Arteriosclerosis, Thrombosis, and Vascular Biology 41, no. 8 (2021): 2277–92. http://dx.doi.org/10.1161/atvbaha.121.316472.

Full text

Abstract:

Objective: Healing processes, particularly reendothelialization, are essential for vascular homeostasis after plain old balloon angioplasty and stent implantation. Drug-eluting stents (DES) are commonly used for percutaneous coronary intervention because restenosis rates are reduced as compared with bare metal stents (BMS). However, in addition to understanding the nature of regenerated endothelial cells, concerns over incomplete stent healing persist, and the molecular effects of antiproliferative drug coatings on endothelium remain poorly understood. Approach and Results: We used the rabbit

APA, Harvard, Vancouver, ISO, and other styles

5

Narbute, Inga, Sanda Jēgere, Indulis Kumsārs, et al. "Long-term Clinical Results for Randomised Comparison of Paclitaxel-eluting versus Bare-metal Stents in Unprotected Left Main Coronary Artery Disease." Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 63, no. 4-5 (2009): 243–48. http://dx.doi.org/10.2478/v10046-009-0037-2.

Full text

Abstract:

Long-term Clinical Results for Randomised Comparison of Paclitaxel-eluting versus Bare-metal Stents in Unprotected Left Main Coronary Artery Disease To optimise percutaneous coronary intervention (PCI) strategy for unprotected left main (ULMCA) disease we performed a randomised study: IVUS-guided bare metal stent (BMS) versus paclitaxel-eluting stent (PES) implantation after lesion pre-treatment with cutting balloon (CB) for unprotected LM lesions. The purpose of this randomized study was to evaluate six-month and three-year clinical results. Several recent publications have demonstrated good

APA, Harvard, Vancouver, ISO, and other styles

6

Leshkevich, Ch F., E. V. Kovsh, G. A. Sergeev, A. B. Maximchik, D. N. Boncevich, and I. E. Adzerikho. "ASSESSMENT OF INTERVENTION TREATMENT OF UNSTABLE ANGINA OF PATIENTS OF DIABETES MELLITUS TYPE 2." Health and Ecology Issues, no. 4 (December 28, 2008): 34–39. http://dx.doi.org/10.51523/2708-6011.2008-5-4-6.

Full text

Abstract:

The purpose of the study is a comparative assessment of the immediate and long-term results using Sirolimus - Eluting Stents (SES) and Bare-Metal Stent (BMS) in patients with unstable angina and diabetes mellitus type 2.

APA, Harvard, Vancouver, ISO, and other styles

7

Sabti, Zaid, and Raban Jeger. "Vollständig resorbierbare Stents – eine neue Ära in der Behandlung der koronaren Herzkrankheit?" Praxis 106, no. 2 (2017): 85–89. http://dx.doi.org/10.1024/1661-8157/a002584.

Full text

Abstract:

Zusammenfassung. Die perkutane Ballonangioplastie revolutionierte die Behandlung der koronaren Herzkrankheit. Der Einsatz von Gefässstützen (Stents) setzte diese Revolution fort. Nach den reinen Metallstents (Bare metal stents, BMS) und den Medikamenten-beschichteten Stents (drug-eluting stents, DES) folgen nun bioresorbierbare Stents (bioresorbable vascular scaffolds, BVS). Im Gegensatz zu den ersten zwei Stent-Generationen werden die BVS nach einer bestimmten Zeit vollständig abgebaut und versprechen eine Antwort für bisher ungelöste Probleme von BMS und DES.

APA, Harvard, Vancouver, ISO, and other styles

8

Apostolovic, Svetlana, Zoran Perisic, Miloje Tomasevic, Goran Stankovic, Milan Pavlovic, and Sonja Salinger-Martinovic. "Late thrombosis of coronary bare-metal stent: Case report." Srpski arhiv za celokupno lekarstvo 134, no. 3-4 (2006): 155–58. http://dx.doi.org/10.2298/sarh0604155a.

Full text

Abstract:

Stent thrombosis remains the primary cause of death after percutaneous coronary interventions (PCI). Despite modern concepts of PCI, stent thrombosis occurs in 0.5% -2% of elective procedures and even 6% of patients with the acute coronary syndrome (ACS). Stent thrombosis most often develops within the first 48 hours after the PCI, and rarely after a week of stent implantation. Angiographically documented late (>6 months) thrombosis of coronary bare-metal stent (BMS) is rare, because the stent endothelialization is considered to be completed after four weeks of the intervention. Our patient

APA, Harvard, Vancouver, ISO, and other styles

9

Kayani, Azhar Mahmood, Syed Nadeem Hassan Rizvi, Khusrow A. Niazi, et al. "CLINICAL EVALUATION OF THE INDIGENOUSLY MANUFACTURED REJUVENATE® BARE METAL STENT SYSTEM IN PAKISTANI PATIENTS WITH CORONARY ARTERY DISEASE." Pakistan Heart Journal 54, no. 3 (2021): 261–67. http://dx.doi.org/10.47144/phj.v54i3.2169.

Full text

Abstract:

Objectives: The aim of this pilot study was the ﬁrst-in-man evaluation of the safety, feasibility, deliverability, and efficiency of the newly developed REJUVENATE® bare metal stent system in coronary artery disease. Methodology: Current study was a pilot non-randomized, multi-centric and prospective study which was intended to study the safety of the REJUVENATE® bare metal stent in Pakistani population over 10 months. Study endpoints included target vessel related myocardial infarction, stent thrombosis, in-stent restenosis, stroke and death. The diameter of the target lesions selected was be

APA, Harvard, Vancouver, ISO, and other styles

10

Pradeepa, P., S. S. Murugan, Sangeetha V. Naveen, and T. S. Kumaravel. "Evaluation of Mechanical Hemolysis of Bare Metallic and Drug-Eluting Cardiovascular Stents." Indian Journal Of Science And Technology 18, no. 13 (2025): 1079–86. https://doi.org/10.17485/ijst/v18i13.645.

Full text

Abstract:

Objectives: To investigate the hemolytic potential of different types of experimental cardiovascular stents [Bare Metal Stents (BMS), Sirolimus Eluting Stents (SES), and Everolimus Eluting Stents (EES)] in an in vitro study using a bovine blood circulatory model. Methods : Fresh bovine blood was circulated through the loop containing the stents, using the peristaltic pump for 6 hours at 37°C at a constant flow of 200 mL/minute. Plasma Free Hemoglobin (PFH) was measured spectrophotometrically at defined intervals. The Normalized Index of Hemolysis (NIH) and the Modified Index of Hemolysis (MIH)

APA, Harvard, Vancouver, ISO, and other styles

11

Djuric, Predrag, Slobodan Obradovic, Zoran Stajic, et al. "Very late stent thrombosis of bare-metal coronary stent nine years after primary percutaneous coronary intervention." Vojnosanitetski pregled 73, no. 8 (2016): 774–78. http://dx.doi.org/10.2298/vsp141222053d.

Full text

Abstract:

Introduction. Stent thrombosis (ST) in clinical practice can be classified according to time of onset as early (0?30 days after stent implantation), which is further divided into acute (< 24 hours) and subacute (1?30 days), late (> 30 days) and very late (> 12 months). Myocardial reinfaction due to very late ST in a patient receiving antithrombotic therapy is very rare, and potentially fatal. The procedure alone and related mechanical factors seem to be associated with acute/subacute ST. On the other hand, in-stent neoathero-sclerosis, inflammation, premature cessation of antiplatelet

APA, Harvard, Vancouver, ISO, and other styles

12

Sukmana, Irza, Arifo Gunawan Chyanegoro, and Agus Sugiri. "Biomedical Material for Stent Application: Current Status and Future Challenges." Journal of Applied Science, Engineering and Technology 1, no. 2 (2021): 60. http://dx.doi.org/10.47355/aset.v1i2.18.

Full text

Abstract:

Cardiovascular disease is the leading cause of death worldwide. Arterial stenting as a transluminal angioplasty procedure allows re-opening of narrowed vessels and restoring normal blood flow with stent placement. The development of stents ed at the end of 19 century with bare-metal stents (BMS). Now, it has been based on the application of biodegradable or natural decomposed and coated stents. The coated stent has been found to improve BMS properties in terms of biocompatibility, cytotoxicity, and better mechanical and biophysical properties. Also, a biodegradable stent may support the blood

APA, Harvard, Vancouver, ISO, and other styles

13

Gao, Junqing Q., Jianpu P. Zheng, Huigen G. Jin, et al. "A new rapamycin-abluminally coated chitosan/heparin stent system accelerates early re-endothelialisation and improves anti-coagulant properties in porcine coronary artery models." Clinical & Investigative Medicine 37, no. 6 (2014): 395. http://dx.doi.org/10.25011/cim.v37i6.22244.

Full text

Abstract:

Purpose: Drug-eluting stents (DES) in percutaneous coronary intervention are more effective in preventing in-stent restenosis compared with bare metal stents (BMS); however, DES may cause late stent thrombosis, which has limited its use. In this study, the functional properties of a newly developed DES (RAP/CS/HEP), in which rapamycin was abluminally-loaded onto a chitosan/heparin coating stent (CS/HEP), were investigated in large animal artery injury models. Methods: The effectiveness of BMS, RAP (the traditional version of rapamycin DES), CS/HEP and RAP/CS/HEP stents in preventing coagulatio

APA, Harvard, Vancouver, ISO, and other styles

14

Lukman, Siti Khadijah, Rania Hussien Al-Ashwal, Ahmad Zahran Md. Khudzari, and Syafiqah Saidin. "Emerging of cardiovascular metal stent: A review on drug-eluting stent towards the utilisation of herbal coating." Malaysian Journal of Fundamental and Applied Sciences 15, no. 2 (2019): 225–31. http://dx.doi.org/10.11113/mjfas.v15n2.1115.

Full text

Abstract:

Metal stents used in the treatment of percutaneous coronary intervention (PCI) have revolutionized in treating atherosclerosis disease. Starting from the emergence of bare metal stent (BMS), this stent has been progressively developed into drug-eluting stent (DES) and biodegradable stent. By focusing on DES, various drugs have been used to coat metal stent with the aims to overcome in-stent restenosis and stent thrombosis. Even though, both problems are covered successfully by DES, however, DES projects long term complications including late stent thrombosis and delayed endotheliasation. There

APA, Harvard, Vancouver, ISO, and other styles

15

P, Pradeepa, S. Murugan S, V. Naveen Sangeetha, and S. Kumaravel T. "Evaluation of Mechanical Hemolysis of Bare Metallic and Drug-Eluting Cardiovascular Stents." Indian Journal of Science and Technology 18, no. 13 (2025): 1079–86. https://doi.org/10.17485/IJST/v18i13.645.

Full text

Abstract:

Abstract <strong>Objectives:</strong> To investigate the hemolytic potential of different types of experimental cardiovascular stents [Bare Metal Stents (BMS), Sirolimus Eluting Stents (SES), and Everolimus Eluting Stents (EES)] in an in vitro study using a bovine blood circulatory model. <strong>Methods :</strong> Fresh bovine blood was circulated through the loop containing the stents, using the peristaltic pump for 6 hours at 37°C at a constant flow of 200 mL/minute. Plasma Free Hemoglobin (PFH) was measured spectrophotometrically at defined intervals. The Normalized Inde

APA, Harvard, Vancouver, ISO, and other styles

16

Kamann, Stefanie, Tobias Haase, Nicola Stolzenburg, et al. "Bare Metal Stents on Resveratrol-Coated Balloons in Porcine Coronary and Peripheral Arteries." International Journal of Molecular Sciences 22, no. 23 (2021): 13099. http://dx.doi.org/10.3390/ijms222313099.

Full text

Abstract:

Balloon angioplasty and stent implantation are standard techniques to reopen stenotic vessels. Often, balloons or stents coated with cytostatic drugs are used to prevent re-occlusion of the arteries. Resveratrol, which is known for its numerous beneficial effects on cardiovascular health, is used as an antioxidant additive on paclitaxel-coated balloon catheters. What is still unclear is whether resveratrol-only balloon coating in combination with a bare metal stent (BMS) also has positive effects on vascular healing. Here, we analyzed neointimal thickening, fibrin deposition, inflammation, vas

APA, Harvard, Vancouver, ISO, and other styles

17

Li, Long, Xu Wang, Bin Yang, et al. "Validation and comparison of drug eluting stent to bare metal stent for restenosis rates following vertebral artery ostium stenting: A single-center real-world study." Interventional Neuroradiology 26, no. 5 (2020): 629–36. http://dx.doi.org/10.1177/1591019920949371.

Full text

Abstract:

Background and purpose While drug-eluting stents (DES) have been widely applicated in coronary stenosis, uncertainty persists concerning the relative performance and clinical benefit in patients undergoing vertebral artery stenting when compared with a bare metal stent (BMS). We sought to compare in-stent restenosis (ISR) rates of DES and BMS in the treatment of vertebral artery ostium (VAO) stenosis. Materials and Methods This study analyzed a single-center prospective cohort. Over 1.5-year period (January 2014-June 2015), 137 consecutive patients underwent VAO stenting involving deployment o

APA, Harvard, Vancouver, ISO, and other styles

18

Mølstad, Per Morten, Jan Erik Nordrehaug, Terje K. Steigen, et al. "Drug-Eluting versus Bare-Metal Stents in Saphenous Vein Grafts Compared to Native Coronary Vessels: The Norwegian Coronary Stent Trial Study." Cardiology 147, no. 1 (2021): 14–22. http://dx.doi.org/10.1159/000521085.

Full text

Abstract:

Background: Drug-eluting stents (DES) reduce target lesion revascularization (TLR) with no effect on mortality or myocardial infarction (MI) compared to bare-metal stents (BMS) in native vessels. Randomized stent studies in saphenous vein grafts (SVG) are few and the reported effects are ambiguous. The Norwegian Coronary Stent Trial study is the first to randomize lesions to percutaneous coronary intervention in native vessels and SVG. Aims: The aim of this study was to compare the rate of mortality, MI, and TLR across stent and vessel types. Methods: In this substudy, 6,087 patients with a si

APA, Harvard, Vancouver, ISO, and other styles

19

Nuttall, Gregory A., Michael J. Brown, John W. Stombaugh, et al. "Time and Cardiac Risk of Surgery after Bare-metal Stent Percutaneous Coronary Intervention." Anesthesiology 109, no. 4 (2008): 588–95. http://dx.doi.org/10.1097/aln.0b013e318186ddf8.

Full text

Abstract:

Background The duration of time that elective noncardiac surgery (NCS) should be delayed after percutaneous coronary intervention (PCI) with bare metal stents (BMSs) is unknown. Methods This large, single-center, retrospective study examined the relation between complication rate in patients with BMSs undergoing NCS and the duration of time between PCI and NCS. Primary endpoints included in-hospital major adverse cardiac events (death, myocardial infarction, stent thrombosis, or repeat revascularization with either coronary artery bypass grafting or PCI of the target vessel) and bleeding event

APA, Harvard, Vancouver, ISO, and other styles

20

CHEN, Ming, Bo ZHENG, Zheng WU, et al. "Efficacy and safety of a novel nano-porous polymer-free sirolimus-eluting stent in pigs." Chinese Medical Journal 126, no. 24 (2013): 4731–35. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20123267.

Full text

Abstract:

Background Drug-eluting stents represent a major advance in interventional cardiology. However, the current drug-eluting stents have significant limitations. One of the major problems is very late stent thrombosis, which is likely caused by inflammation and a hypersensitivity reaction related to a polymer on the stent. A polymer-free sirolimus-eluting stent with a unique nano-porous surface has been developed. This study aimed to evaluate this novel polymer-free sirolimus-eluting stent for its efficacy and safety in a pig model. Methods Stents were directly coated with sirolimus (a drug concen

APA, Harvard, Vancouver, ISO, and other styles

21

Mwipatayi, Bibombe Patrice, Shannon Thomas, Donna Angel, Jackie Wong, and Vikram Vijayan. "Stent outcomes for infrapopliteal arterial occlusive disease." Vascular 21, no. 3 (2013): 121–28. http://dx.doi.org/10.1177/1708538113478734.

Full text

Abstract:

This study aimed to determine if the different stent types used in the treatment of infrapopliteal arterial occlusive disease provide any significant advantage over one another at 6 and 12-month follow-up. Consecutive patients undergoing stenting of infrapopliteal lesions were enrolled into a non-randomised prospective registry and followed-up for 1 year. Outcome measures included binary restenosis, target lesion revascularisation, major amputation, and change in Rutherford-Becker score and ankle-brachial index (ABI). Thirty-three patients were enrolled including four patients with bilateral d

APA, Harvard, Vancouver, ISO, and other styles

22

DURRANI, T., A. QADEER, M. JUNAID, I. HUSSAIN, F. KHAN, and H. DURRANI. "CLINICAL OUTCOMES OF PRIMARY PERCUTANEOUS CORONARY INTERVENTION USING DES VS BMS In ACUTE CORONARY SYNDROME PATIENTS WITH LEFT ANTERIOR DESCENDING ARTERY INVOLVEMENT: A COMPARATIVE STUDY." Biological and Clinical Sciences Research Journal 2024, no. 1 (2024): 1155. http://dx.doi.org/10.54112/bcsrj.v2024i1.1155.

Full text

Abstract:

Acute coronary syndrome (ACS) with left anterior descending (LAD) artery involvement often leads to more extensive myocardial infarction. Choosing between drug-eluting stents (DES) and bare-metal stents (BMS) for revascularisation in these patients is a topic of clinical relevance. While drug-eluting stents are the gold standard, bare-metal stents remain an essential option for patients with specific considerations such as an inability to complete the recommended duration of DAPT, advanced age, concomitant oral anticoagulation, cancer, affordability issues, increased bleeding risk, and planned

APA, Harvard, Vancouver, ISO, and other styles

23

Zähringer, Markus, Marc Sapoval, Peter M. T. Pattynama, et al. "Sirolimus-Eluting versus Bare-Metal Low-Profile Stent for Renal Artery Treatment (GREAT Trial): Angiographic Follow-up after 6 Months and Clinical Outcome up to 2 Years." Journal of Endovascular Therapy 14, no. 4 (2007): 460–68. http://dx.doi.org/10.1177/152660280701400405.

Full text

Abstract:

Purpose: To evaluate the patency of sirolimus-eluting stents (SES) compared to bare-metal stents (BMS) in the treatment of atherosclerotic renal artery stenosis (RAS). Methods: Between November 2001 to June 2003, 105 consecutive symptomatic patients (53 men; mean age 65.7 years) with RAS were treated with either a bare-metal (n=52) or a drug-eluting (n=53) low-profile Palmaz-Genesis peripheral stent at 11 centers in a prospective nonrandomized trial. The primary endpoint was the angiographic result at 6 months measured with quantitative vessel analysis by an independent core laboratory. Second

APA, Harvard, Vancouver, ISO, and other styles

24

Diaz-Rodriguez, Sergio, Charlotte Rasser, Jules Mesnier, et al. "Coronary stent CD31-mimetic coating favours endothelialization and reduces local inflammation and neointimal development in vivo." European Heart Journal 42, no. 18 (2021): 1760–69. http://dx.doi.org/10.1093/eurheartj/ehab027.

Full text

Abstract:

Abstract Aims The rapid endothelialization of bare metal stents (BMS) is counterbalanced by inflammation-induced neointimal growth. Drug-eluting stents (DES) prevent leukocyte activation but impair endothelialization, delaying effective device integration into arterial walls. Previously, we have shown that engaging the vascular CD31 co-receptor is crucial for endothelial and leukocyte homeostasis and arterial healing. Furthermore, we have shown that a soluble synthetic peptide (known as P8RI) acts like a CD31 agonist. The aim of this study was to evaluate the effect of CD31-mimetic metal stent

APA, Harvard, Vancouver, ISO, and other styles

25

Chitkara, Kamal, and Anthony Gershlick. "Second- versus First-generation Drug-eluting Stents." Interventional Cardiology Review 5, no. 1 (2010): 23. http://dx.doi.org/10.15420/icr.2010.5.1.23.

Full text

Abstract:

Drug-eluting stents (DES) have demonstrated their superiority over bare-metal stents (BMS) with respect to in-stent restenosis and the need for repeat revascularisation. BMS and first-generation DES, such as sirolimus-eluting (Cypher®) and paclitaxel-eluting stents (Taxus®), have further improved the results of percutaneous coronary intervention (PCI) by improving early results and reducing the risk of restenosis. However, there is currently a debate as to the safety of these first-generation DES given the potential for late stent thrombosis, especially after discontinuation of dual-antiplatel

APA, Harvard, Vancouver, ISO, and other styles

26

Chavez, Jose F., Jacob A. Doll, Anuj Mediratta, et al. "Factors Associated with the Use of Drug-Eluting Stents in Patients Presenting with Acute ST-Segment Elevation Myocardial Infarction." Cardiology Research and Practice 2015 (2015): 1–7. http://dx.doi.org/10.1155/2015/528753.

Full text

Abstract:

Background. Drug-eluting stents (DES) have proven clinical superiority to bare-metal stents (BMS) for the treatment of patients with ST-segment elevation myocardial infarction (STEMI). Decision to implant BMS or DES is dependent on the patient’s ability to take dual antiplatelet therapy. This study investigated factors associated with DES placement in STEMI patients.Methods. Retrospective analysis was performed on 193 patients who presented with STEMI and were treated with percutaneous coronary intervention at an urban, tertiary care hospital. Independent factors associated with choice of sten

APA, Harvard, Vancouver, ISO, and other styles

27

Pranit Kamdar. "Recent Advancements in Drug-Eluting Stents: A Comprehensive Review." Darpan International Research Analysis 12, no. 3 (2024): 605–16. http://dx.doi.org/10.36676/dira.v12.i3.116.

Full text

Abstract:

Drug-eluting stents (DES) have revolutionized the field of interventional cardiology by significantly reducing restenosis rates compared to bare-metal stents (BMS). Over the past two decades, there have been remarkable advancements in DES technology aimed at improving efficacy, safety, and long-term outcomes. This comprehensive review provides an overview of recent developments in DES design, drug formulations, coatings, and delivery systems. It discusses the clinical evidence supporting the efficacy and safety of next-generation DES and explores emerging strategies to address remaining challe

APA, Harvard, Vancouver, ISO, and other styles

28

Mohani, Amir F., Srikanth Penumetsa, Amin Daoulah, Gregory Giugliano, and Amir Lotfi. "Cardiovascular Outcomes in Patients on Hemodialysis following Drug-Eluting versus Bare-Metal Coronary Stents." Cardiology Research and Practice 2018 (2018): 1–7. http://dx.doi.org/10.1155/2018/4934982.

Full text

Abstract:

Aim. This study sought to compare short- and long-term outcomes of drug-eluting stents (DESs) versus bare-metal stents (BMSs) implantation in patients with end-stage renal disease on hemodialysis (ESRD-HD) undergoing percutaneous coronary intervention (PCI). Methods. Adult patients with ESRD-HD who underwent PCI at all nonfederal hospitals in Massachusetts between July 1, 2003, and September 30, 2007, were stratified based on the stent type placed at index hospitalization: DES or BMS. The primary outcome compared was a composite of all-cause death, myocardial infarction (MI), congestive heart

APA, Harvard, Vancouver, ISO, and other styles

29

Bagyura, Zsolt, Loretta Kiss, Kristóf Hirschberg, et al. "Association between VEGF Gene Polymorphisms and In-Stent Restenosis after Coronary Intervention Treated with Bare Metal Stent." Disease Markers 2017 (2017): 1–7. http://dx.doi.org/10.1155/2017/9548612.

Full text

Abstract:

Background. In-stent restenosis (ISR) is the gradual narrowing of the vessel lumen after coronary stent implantation due to the increase in vascular smooth muscle cell proliferation. Vascular endothelial growth factor (VEGF) protein plays an important role in this process. Our aim was to analyze the association of single nucleotide polymorphisms of the VEGF gene (rs2010963 and rs6999447) with the occurrence of ISR after coronary artery bare metal stent (BMS) implantation. Methods. 205 patients with a history of BMS implantation and a repeated coronarography were prospectively enrolled. Patient

APA, Harvard, Vancouver, ISO, and other styles

30

Kischkel, Sabine, Niels Grabow, Carsten M. Bünger, and Anja Püschel. "Impact of statins on vascular scaffolds response in porcine carotid arteries." Current Directions in Biomedical Engineering 7, no. 2 (2021): 101–4. http://dx.doi.org/10.1515/cdbme-2021-2026.

Full text

Abstract:

Abstract Surgical treatments of arterial occlusive disease with fully absorbable polymeric scaffolds, as a potential alternative to permanent metallic stents, are increasingly penetrating the clinical field. An addition part of the management of patients suffering from vascular diseases is the administration of statins. In this study, absorbable x-ray marked PLLA-based polymer scaffolds and permanent bare-metal stents (BMS) were implanted interventionally into both common carotid arteries (CCA) of 6 healthy female pigs via the left common iliac artery (8F-sheath). The pigs were administered du

APA, Harvard, Vancouver, ISO, and other styles

31

Kalburgi, Veeraj. "Drug eluting stents versus bare metal stents in coronary artery disease patients: outcomes and complications." International Journal of Research in Medical Sciences 7, no. 1 (2018): 260. http://dx.doi.org/10.18203/2320-6012.ijrms20185392.

Full text

Abstract:

Background: To date, data regarding the long-term safety and efficacy of BMS and DES implantation in a real-world population are limited. Thus, this study was designed to study the complications, early and late outcomes of drug-eluting stents (DES) versus bare metal stents (BMS) after implantation in coronary artery disease (CAD) patients up to 6months follow-up period.Methods: This was a single-center, hospital-based, prospective study conducted at a tertiary care center in India. Records of 250 patients who underwent percutaneous coronary intervention (PCI) in the period of January to Decemb

APA, Harvard, Vancouver, ISO, and other styles

32

Beshchasna, Natalia, Muhammad Saqib, Honorata Kraskiewicz, et al. "Recent Advances in Manufacturing Innovative Stents." Pharmaceutics 12, no. 4 (2020): 349. http://dx.doi.org/10.3390/pharmaceutics12040349.

Full text

Abstract:

Cardiovascular diseases are the most distributed cause of death worldwide. Stenting of arteries as a percutaneous transluminal angioplasty procedure became a promising minimally invasive therapy based on re-opening narrowed arteries by stent insertion. In order to improve and optimize this method, many research groups are focusing on designing new or improving existent stents. Since the beginning of the stent development in 1986, starting with bare-metal stents (BMS), these devices have been continuously enhanced by applying new materials, developing stent coatings based on inorganic and organ

APA, Harvard, Vancouver, ISO, and other styles

33

Falkowski, Aleksander, Hubert Bogacki, and Marcin Szemitko. "Assessment of Mortality and Factors Affecting Outcome of Use of Paclitaxel-Coated Stents and Bare Metal Stents in Femoropopliteal PAD." Journal of Clinical Medicine 9, no. 7 (2020): 2221. http://dx.doi.org/10.3390/jcm9072221.

Full text

Abstract:

The use of drug-coated devices in intravascular therapy is aimed at preventing neointimal hyperplasia caused by excessive proliferation of vascular smooth muscle and thereby restenosis. Although its use seemed initially promising, a recent publication has shown an increased risk of mortality with paclitaxel-coated devices, and there is an urgent need to reaffirm assessments of drug-eluting stents (DES). Objective: The aim of the study was to compare mortality and effectiveness of paclitaxel-coated stents and bare-metal stents (BMS) in the treatment of peripheral arterial disease (PAD) with lon

APA, Harvard, Vancouver, ISO, and other styles

34

Otsuka, Fumiyuki, Masataka Nakano, Elena Ladich, Frank D. Kolodgie, and Renu Virmani. "Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement." Thrombosis 2012 (November 21, 2012): 1–16. http://dx.doi.org/10.1155/2012/608593.

Full text

Abstract:

Several randomized and observational studies have reported steady increase in cumulative incidence of late and very late ST (LST/VLST) following first-generation drug-eluting stents (DES: sirolimus-(SES) and paclitaxel-(PES)) up to 5 years. Pathologic studies have identified uncovered struts as the primary substrate responsible for LST/VLST following DES, where delayed arterial healing is associated with stent struts penetrating into the necrotic core, long/overlapping stents, and bifurcation stenting especially in flow divider region. Grade V stent fracture also induces LST/VLST and restenosi

APA, Harvard, Vancouver, ISO, and other styles

35

Celik, Ibrahim Etem, Mikail Yarlioglues, Alparslan Kurtul, et al. "Preprocedural Albumin Levels and Risk of In-Stent Restenosis After Coronary Stenting With Bare-Metal Stent." Angiology 67, no. 5 (2015): 478–83. http://dx.doi.org/10.1177/0003319715598084.

Full text

Abstract:

In-stent restenosis (ISR) remains a significant clinical problem in patients with coronary artery disease treated with percutaneous coronary intervention. Decreased serum albumin (SA) level is related to an increased risk of cardiovascular events. The aim of the present study was to assess whether SA levels at admission are an independent predictor of ISR in patients undergoing bare-metal stent (BMS) implantation. A total of 341 patients (aged 61 ± 11, 65.4% men) with a history of BMS implantation and a further control coronary angiography due to stable angina pectoris (SAP) were included. The

APA, Harvard, Vancouver, ISO, and other styles

36

Bakhtar, Vijay P., Niyati V. Bakhtar, and Sameer P. Chaudhari. "Study of efficacy and safety of drug eluting stent versus bare metal stent in ST elevation MI." International Journal of Research in Medical Sciences 7, no. 8 (2019): 3149. http://dx.doi.org/10.18203/2320-6012.ijrms20193410.

Full text

Abstract:

Background: The present study was conducted with the aim of determining whether drug-elutingstents are superior to uncoated stents in the setting of primaryPCI in terms of occurrence of serious adverse cardiac events.Methods: In this prospective, single blind, randomized study, 20 to 80 years old patients with acute myocardial infarction with ST-segment elevation with >30 minutes of chest pain and at least 1 mm of ST-segment elevation in at least two standard leads or a new LBBB or 2 mm of ST-segment elevation in at least two contiguous leads were included. Patients were randomly assigned t

APA, Harvard, Vancouver, ISO, and other styles

37

Reifart, Nicolaus, Mariann Gyöngyösi, Hauptmann Karl-Eugen, et al. "Pre-clinical and Clinical Study Results for the Coracto™ Rapamycin-eluting Stent – A New-generation Drug-eluting Stent." Interventional Cardiology Review 5, no. 1 (2010): 39. http://dx.doi.org/10.15420/icr.2010.5.1.39.

Full text

Abstract:

First- and second-generation drug-eluting stents (DES) have successfully decreased the rate of restenosis compared with bare-metal stents (BMS); however, the incidence of late stent thrombosis, which mostly occurs after the implantation of DES, and chronic restenosis are still important medical problems. A new generation of DES, the Coracto™ rapamycin-eluting stent (RES), has the potential to reduce late stent thrombosis and the risk of chronic restenosis due to the totally biodegradable polymer providing a controlled drug release. In brief, the results of the two pre-clinical studies proved t

APA, Harvard, Vancouver, ISO, and other styles

38

Yang, Yi-Xing, Yin Liu, Chang-Ping Li, Peng-Ju Lu, Jiao Wang, and Jing Gao. "Clinical Outcomes of Drug-Eluting versus Bare-Metal In-Stent Restenosis after the Treatment of Drug-Eluting Stent or Drug-Eluting Balloon: A Systematic Review and Meta-Analysis." Journal of Interventional Cardiology 2020 (June 27, 2020): 1–11. http://dx.doi.org/10.1155/2020/8179849.

Full text

Abstract:

Background. Although drug-eluting stents (DES) have reduced the rates of in-stent restenosis (ISR) compared with bare-metal stents (BMS), DES related ISR (DES-ISR) still occurs and outcomes of DES-ISR remain unclear. The objective of this meta-analysis was to investigate the long-term clinical outcomes of patients with DES-ISR compared with patients with BMS related ISR (BMS-ISR) after the treatment of DES or drug-eluting balloon (DEB). Methods and results. We searched the literature in the main electronic databases including PUBMED, EMBASE, Cochrane Library, and Web of Science. The primary en

APA, Harvard, Vancouver, ISO, and other styles

39

Siddiqui, Muhammad U., Eric Warner, Joey Junarta, et al. "Outcomes of Drug-Eluting Stents in comparison to Bare Metal Stents in Cancer Patients with Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis." Journal of Interventional Cardiology 2024 (April 30, 2024): 1–9. http://dx.doi.org/10.1155/2024/3072909.

Full text

Abstract:

Background. Studies have demonstrated poor prognosis in cancer patients who undergo percutaneous coronary intervention (PCI) for coronary artery disease (CAD). Cancer patients receiving PCI are at increased risk of in-stent thrombosis, bleeding, hospital readmissions, and cardiovascular and noncardiovascular mortality when compared to patients without cancer. It is unclear if the poor outcomes in cancer patients are related to the stent type utilized for PCI. This meta-analysis attempts to identify differences in efficacy and safety outcomes when comparing drug-eluting stents (DESs) with bare

APA, Harvard, Vancouver, ISO, and other styles

40

Polanec, B., J. Kramberger, and S. Glodez. "A review of production technologies and materials for manufacturing of cardiovascular stents." Advances in Production Engineering & Management 15, no. 4 (2020): 390–402. http://dx.doi.org/10.14743/apem2020.4.373.

Full text

Abstract:

The purpose of this article is to give a general overview of the production technologies of stents with consideration of their design and materials. Since the beginning of the use of stents in medicine for atherosclerosis treatment, their development has changed rapidly. Various stents have also been developed with the development of materials science, treatment techniques and new manufacturing processes. In this way the development has shifted from the initial bare-metal stents (BMS), to drug-eluting stents (DES) and bio-resorbable stents (BRS), which are made of biodegradable polymers or met

APA, Harvard, Vancouver, ISO, and other styles

41

Chhetry, Minar, Ilhwan Yeo, Emmanuel Moustakakis, and Xuming Dai. "A CASE OF “VERY” VERY LATE STENT THROMBOSIS IN A BARE METAL STENT(BMS)." Journal of the American College of Cardiology 77, no. 18 (2021): 2518. http://dx.doi.org/10.1016/s0735-1097(21)03873-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Satrijo, Budi. "Primary Percutaneous Intervention for ST-Elevation Myocardial Infarction Patients: A State of The Art." Heart Science Journal 3, no. 2 (2022): 1–2. http://dx.doi.org/10.21776/ub.hsj.2022.003.02.1.

Full text

Abstract:

Primary PCI is the preferred reperfusion strategy in patients with STEMI within 12 h of symptom onset. Angiographically successful PPCI was defined as less than 30% residual stenosis by visual assessment and grade 3 TIMI flow achievement. Radial access is preferred over femoral access. Drug eluting stent (DES) implantation is more superior than bare metal stent (BMS) implantation or balloon angioplasty. In STEMI patients with cardiogenic shock, non-infarct related artery PCI during the index procedure should be considered.

APA, Harvard, Vancouver, ISO, and other styles

43

Murat, Sani Namik, Mikail Yarlioglues, Ibrahim Etem Celik, et al. "The Relationship Between Lymphocyte-to-Monocyte Ratio and Bare-Metal Stent In-Stent Restenosis in Patients With Stable Coronary Artery Disease." Clinical and Applied Thrombosis/Hemostasis 23, no. 3 (2016): 235–40. http://dx.doi.org/10.1177/1076029615627340.

Full text

Abstract:

In-stent restenosis (ISR) is a common clinical problem in patients with coronary artery disease treated with percutaneous coronary intervention. Inflammatory process plays a pivotal role in the development of ISR. Both lymphocytes and monocytes are associated with inflammatory status. Recently, it has been shown that the lymphocyte-to-monocyte ratio (LMR) is a novel inflammatory marker. We aimed to investigate the association of serum LMR levels and ISR in patients undergoing bare-metal stent (BMS) implantation. The study included 273 patients (aged 61 ± 11 years, 66.5% men) with a history of

APA, Harvard, Vancouver, ISO, and other styles

44

Panaich, Sidakpal, Theodore Schreiber, and Cindy Grines. "Bioresorbable Scaffolds." Interventional Cardiology Review 9, no. 3 (2014): 175. http://dx.doi.org/10.15420/icr.2014.9.3.175.

Full text

Abstract:

Percutaneous coronary intervention (PCI) has undergone major advances including the evolution in stent technology, from bare metal stents (BMS), to their drug eluting counterparts, to the development of bioresorbable scaffolds (BRS). The primary notion of BRS was to facilitate complete vascular healing and restore normal endothelial function following the resorption of stent scaffold while providing equivalent mechanical properties of a metallic drug eluting stents (DES) in the earlier stages. BRS provide attractive physiologic advancements over the existing DES and have shown promising result

APA, Harvard, Vancouver, ISO, and other styles

45

Smits, Pieter C. "A Comparison of Drug-eluting Stents for Percutaneous Coronary Intervention – Background, Rationale and Design of the COMPARE Trial." European Cardiology Review 5, no. 2 (2009): 69. http://dx.doi.org/10.15420/ecr.2009.5.2.69.

Full text

Abstract:

Drug-eluting stents (DES) can reduce the risk of restenosis associated with percutaneous intervention procedures. However, the first-generation sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) are associated with a higher rate of stent thrombosis compared with bare-metal stents (BMS). Recently, an everolimus-eluting stent (EES) has been developed and data from randomised, controlled trials have demonstrated the safety and efficacy of the EES in the treatment of coronary artery disease. The randomised, all-comer, real-world COMPARE trial has compared the clinical outcomes achi

APA, Harvard, Vancouver, ISO, and other styles

46

Hehrlein, Christoph. "Stent Passivation with Silicon Carbide as a Possible Alternative to Drug-eluting Stents – A Comprehensive Review of Pre-clinical and Clinical Results." Interventional Cardiology Review 4, no. 1 (2009): 60. http://dx.doi.org/10.15420/icr.2009.4.1.60.

Full text

Abstract:

Metallic stenting has significantly improved short-term procedural outcomes and substantially reduced the rate of restenosis in patients undergoing percutaneous coronary interventions (PCI). Drug-eluting stents (DES) are often used in PCI procedures as they have been associated with a significant reduction in the rate of restenosis compared with PCI alone or PCI with bare-metal stents (BMS). However, there have been reports of stent thrombosis (ST) with DES, especially in patients at high risk of death, thrombosis or restenosis. Surface passivation of stents by amorphous silicon carbide (aSiC:

APA, Harvard, Vancouver, ISO, and other styles

47

Alferiev, Ivan S., Bahman Hooshdaran, Benjamin B. Pressly, et al. "Intraprocedural endothelial cell seeding of arterial stents via biotin/avidin targeting mitigates in-stent restenosis." Scientific Reports 12, no. 1 (2022). http://dx.doi.org/10.1038/s41598-022-23820-7.

Full text

Abstract:

AbstractImpaired endothelialization of endovascular stents has been established as a major cause of in-stent restenosis and late stent thrombosis. Attempts to enhance endothelialization of inner stent surfaces by pre-seeding the stents with endothelial cells in vitro prior to implantation are compromised by cell destruction during high-pressure stent deployment. Herein, we report on the novel stent endothelialization strategy of post-deployment seeding of biotin-modified endothelial cells to avidin-functionalized stents. Acquisition of an avidin monolayer on the stent surface was achieved by c

APA, Harvard, Vancouver, ISO, and other styles

48

Dadekian, Gregory A., Jeremy Smith, Nancy E. Morden, and Aaron V. Kaplan. "Abstract 13179: Bare Metal vs Drug Eluting Stent Choice: The Impact of Atrial Fibrillation and Setting of Care Among Medicare Beneficiaries." Circulation 132, suppl_3 (2015). http://dx.doi.org/10.1161/circ.132.suppl_3.13179.

Full text

Abstract:

Background: In treating coronary artery disease, many factors influence the choice of bare metal (BMS) or drug eluting stents (DES), including bleeding risk and suitability for prolonged dual anti-platelet therapy (DAPT). Atrial fibrillation (AF) further complicates this choice. We examined stent selection among Medicare beneficiaries by AF status to explore how cardiologists are managing this complex choice overall and how this choice varies across academic medical centers (AMC). Methods: Using a 100% Medicare denominator file and associated inpatient claims (2008-2012), we identified patient

APA, Harvard, Vancouver, ISO, and other styles

49

Pradhan, Akshyaya, Shubhajeet Roy, Gaurav Chaudhary, Pravesh Vishwakarma, Sharad Chandra, and Md Al Hasibuzzaman. "A tale of two in stent restenosis in same patient: Surprising findings from optical coherence tomography." Clinical Case Reports 11, no. 11 (2023). http://dx.doi.org/10.1002/ccr3.8222.

Full text

Abstract:

Key Clinical MessageThe morphology of in‐stent restenosis (ISR) in drug eluting stents varies greatly from that of bare metal stents. Optical coherence tomography (OCT) is a useful aid for identifying the nature of ISR and planning the treatment accordingly, which may be by intravascular lithotripsy, cutting balloon or Rotablator, which can be used upfront if OCT shows calcified neoatherosclerosis.AbstractRestenosis is the decrease in the diameter of the vessel lumen after the performance of percutaneous intervention (PCI), which may or may not involve the implantation of a stent. The morpholo

APA, Harvard, Vancouver, ISO, and other styles

50

Xiao, Lei, Shuntong Gu, Yonghui Chen, Xiujun Zhang, Yuqiang Wang, and Xiangchen Dai. "Midterm Results of Drug-Coated Balloon and Bare Metal Stent in the Treatment of TASCII C/D Femoropopliteal Artery Occlusive Disease: A Retrospective Multicenter Study." Journal of Endovascular Therapy, November 18, 2023. http://dx.doi.org/10.1177/15266028231209932.

Full text

Abstract:

Purpose: This study aimed to compare midterm efficacy between drug-coated balloon (DCB) and bare metal stent (BMS) in the treatment of TASCII C/D femoropopliteal artery lesions. Methods: The clinical data of patients with TASCII C/D femoropopliteal artery disease admitted to 3 vascular surgery centers from January 2018 to January 2021 were retrospectively analyzed. Patients were divided into DCB group and BMS group. The DCB group was further subdivided into DCB alone subgroup and DCB+BMS subgroup. Study primary outcomes were freedom from clinical-driven target lesion reintervention (FCD-TLR) a

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!